ACHIEVE LIFE SCIENCES INC
ACHVNASDAQ๐ #2534 by market capEarnings Mar 22 ยท PostUS Equity
$6.80โฒ $0.08 (+1.19%)
Market closed ยท at closeTrack ACHV
Get earnings, price moves & breaking news on Telegram
24hโฒ 1.2%
7dโฒ 0.0%
14dโฒ 1.2%
30dโฒ 5.0%
ytdโฒ 36.5%
1yโฒ 72.4%
๐ฆMarket Cap
$700M
Small Cap
๐Revenue Growth (YoY)
-89.3%
Declining
๐Gross Margin
โ
๐ตFCF Margin
34.0%
Strong
โ๏ธP/S Ratio
39.2x
Expensive
Otter Score
โ
Insufficient data
Trading Snapshot
- Day Range
- $6.53 โ $6.89
- 52-Week Range
- $2.62 โ $8.64
- Volume (shares)
- 51,079
- Avg Volume (shares)
- โ
- Shares Outstanding
- 102.9M
- Next Earnings
- 2027-03-22
Fundamentals Snapshot
- Annual Revenue
- โ
- Last Q Revenue
- $114,000
- P/E Ratio
- โ
- P/S Ratio
- 39.2x
- EPS (TTM)
- $-1.55
- Dividend Yield
- โ
ACHIEVE LIFE SCIENCES INC
ACHVFinancial Trends
Financial history unavailable.
About ACHIEVE LIFE SCIENCES INC
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
๐ฆฆ
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
๐Growthโ
โ
โ
โ
โ
โ๏ธValuationโ
โ
โ
โ
โ
โกMomentumโ
โ
โ
โ
โ
Overall Score
Insufficient data
โ/100
Analyst data unavailable.
Latest News & Updates
News unavailable.